NM_000455.5:c.598-1G>A
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000455.5(STK11):c.598-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000455.5 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- familial pancreatic carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: G2P
- Peutz-Jeghers syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Orphanet, Genomics England PanelApp, G2P
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| STK11 | NM_000455.5 | c.598-1G>A | splice_acceptor_variant, intron_variant | Intron 4 of 9 | ENST00000326873.12 | NP_000446.1 | ||
| STK11 | NM_001407255.1 | c.598-1G>A | splice_acceptor_variant, intron_variant | Intron 4 of 8 | NP_001394184.1 | |||
| STK11 | NR_176325.1 | n.1865-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 10 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| STK11 | ENST00000326873.12 | c.598-1G>A | splice_acceptor_variant, intron_variant | Intron 4 of 9 | 1 | NM_000455.5 | ENSP00000324856.6 | |||
| STK11 | ENST00000652231.1 | c.598-1G>A | splice_acceptor_variant, intron_variant | Intron 4 of 8 | ENSP00000498804.1 | |||||
| STK11 | ENST00000585748.3 | c.226-1G>A | splice_acceptor_variant, intron_variant | Intron 6 of 11 | 3 | ENSP00000477641.2 | ||||
| STK11 | ENST00000593219.6 | n.*423-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 10 | 3 | ENSP00000466610.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Peutz-Jeghers syndrome Pathogenic:1
Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with clinical features of Peutz Jeghers syndrome (PMID: 30528796, Invitae). ClinVar contains an entry for this variant (Variation ID: 527837). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 4 of the STK11 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in STK11 are known to be pathogenic (PMID: 15188174, 16287113). For these reasons, this variant has been classified as Pathogenic.
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.598-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 5 of the STK11 gene. This alteration was identified amongst a cohort of 54 Chinese patients with a clinical diagnosis of Peutz-Jeghers syndrome (Jiang YL et al. Cancer Genet, 2019 Jan;230:47-57). This alteration has been observed in at least one individual with a personal and/or family history that is consistent with STK11-related disease (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at